With stocks less than 2% from new highs, will the wall of worry prove too insurmountable or not. Let's ask Adam Parker. He is Tvariat founder and CEO, a CNBC contributor as well.It's good to see you. Thanks for having me. The the last time you were on, you gave us notes, reasons and ways to get defensive in the market.Now, you've given us four ideas to get to for for offense. And you say you got push back from some of your clients who asked why would we get defensive if the price momentum and everything els ...

B&G Foods, Inc. (BGS) posted first-quarter fiscal 2025 results, wherein both top and bottom lines missed the Zacks Consensus Estimate. Both net sales and earnings declined year over year.B&G Foods faced a challenging start to the first quarter of fiscal 2025, impacted by retailer inventory reductions and the timing shift of Easter into the fiscal second quarter. However, the company has seen signs of improving sales trends in recent months. Management remains focused on stabilizing core sales, reshaping the ...

Flutter CEO Peter Jackson told CNBC customer-friendly results in the NCAA's college basketball tournament weighed on overall first-quarter results for FanDuel's parent company. The global sports and online gambling platform reported first-quarter adjusted earnings per share of $1.59, missing Wall Street consensus of $1.89 per share, according to LSEG. Revenue for the period also missed Wall Street expectations, at $3.67 billion versus LSEG estimates of $3.84 billion.The company lowered its full-year U.S. gu ...

Shares of household cleaning name Clorox Co (NYSE:CLX) are down 2.5% at $134.96 at last glance, after the company's fiscal third-quarter earnings and revenue missed estimates. Profits of $1.45 per share also fell below the $1.71 per share from the same quarter a year ago. A slew of analysts slashed their price targets after the event, including Morgan Stanley to $150 from $165. The stock has yet to see any downgrades, as 16 of the 17 brokerages in coverage already carry a "hold" or worse rating.On the chart ...

Core Viewpoint - Integra LifeSciences Holdings Corporation reported an earnings miss for Q1 2025, with adjusted EPS of 41 cents, falling short of estimates and showing a significant year-over-year decline of 25.5% [1][2][11] Financial Performance - Total revenues for Q1 2025 increased by 3.7% year over year to $382.7 million, slightly exceeding consensus estimates by 0.1% [3] - Organic revenue declined by 3.5% year over year, indicating challenges in core operations [3][11] - Gross profit decreased by 6% year over year to $194.4 million, with gross margin contracting by 526 basis points to 50.8% due to a 16.2% rise in the cost of goods sold [6] - Selling, general and administrative expenses rose by 9.5% to $181.5 million, while research and development expenses fell by 8.3% to $24.7 million [6] Segment Performance - Revenues in the Codman Specialty Surgical segment rose by 9.4% year over year to $280.7 million, although organic growth was down by 1.1% [4] - Neurosurgery sales within this segment fell by 4.7% organically, attributed to shipping holds [4] - Tissue Technologies revenues totaled $102 million, down 9.3% year over year, with notable declines in Private Label sales due to supply delays [5] Financial Position - At the end of Q1 2025, the company had approximately $239.1 million in cash and cash equivalents, down from $246.4 million at the end of Q4 2024 [8] - Cumulative net cash outflow from operating activities was $11.26 million, contrasting with cash inflows of $15.76 million a year ago [8] Guidance - For 2025, the company reaffirmed its revenue guidance of $1.650-$1.715 billion, indicating growth of 2.4%-6.5% [9] - Adjusted EPS forecast was reduced to a range of $2.19-$2.29 from a previous range of $2.41-$2.51 [9] - For Q2 2025, expected revenues are projected between $390-$400 million, reflecting a decline of 6.8%-4.4% [10] Strategic Insights - Despite the earnings miss, the company reported positive contributions from the Acclarent acquisition and double-digit growth in several product lines [12] - The company is focusing on advancing its Compliance Master Plan, expanding its international portfolio, and enhancing leadership [12]

Core Viewpoint - Otis Worldwide reported mixed results for Q4 2024, with adjusted earnings missing estimates while net sales exceeded expectations, marking the second consecutive earnings miss after a strong performance in prior quarters [2][5]. Financial Performance - Adjusted earnings were 93 cents per share, missing the Zacks Consensus Estimate of 95 cents by 2.1%, but increased 6.9% year-over-year from 87 cents [5]. - Net sales reached $3.68 billion, slightly above the consensus mark of $3.65 billion, reflecting a 1.5% year-over-year growth, with organic sales increasing by 1.9% [5]. - Adjusted operating margin expanded by 30 basis points to 15.9%, driven by favorable performance in the Service segment [6]. Segment Analysis - **New Equipment Segment**: - Net sales were $1.36 billion, down 7.4% year-over-year, with organic sales declining 6.8% [7]. - Orders decreased by 4% at constant currency, with significant declines in China and EMEA [8]. - Operating margin contracted by 140 basis points to 4.7% due to lower volume and unfavorable mix [9]. - **Service Segment**: - Net sales increased by 7.6% year-over-year to $2.32 billion, supported by a 7.8% rise in organic sales [10]. - Operating margin improved by 50 basis points to 24.5%, aided by higher volume and favorable pricing [11]. Annual Highlights - For 2024, Otis Worldwide reported annual revenues of $14.26 billion, a 0.4% increase from $14.21 billion in 2023, with adjusted EPS rising to $3.83 from $3.54 [12]. - Adjusted operating margin for the year expanded by 50 basis points to 16.5% [12]. Financial Position - As of December 31, 2024, cash and cash equivalents were $2.3 billion, up from $1.27 billion at the end of 2023, while long-term debt increased to $6.97 billion [13]. - Net cash flows from operating activities were $1.56 billion, down from $1.63 billion a year ago, with adjusted free cash flow totaling $1.57 billion [13]. 2025 Outlook - Otis expects net sales between $14.1 billion and $14.4 billion, with organic sales growth projected between 2% and 4% [14]. - Adjusted EPS is anticipated to be between $4 and $4.10, indicating a year-over-year growth of 4-7% [15]. Estimate Trends - There has been a downward trend in estimates, with the consensus estimate shifting down by 5.23% [16]. VGM Scores - Otis Worldwide has a Growth Score of A but lags in Momentum with an F, resulting in an aggregate VGM Score of C [17].